Wilex reports higher revenue, revises full year forecast

Thursday 12 July 2012

Wilex AG, which is developing an antibody treatment and diagnostic for renal cancer, reported gross revenue of about €8.3 million for the fiscal half-year ended in 31 May 2012, up from about €2 million a year earlier.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Germany